Thrombozytenaggregation und Antikoagulation beim akuten Koronarsyndrom

ZUSAMMENFASSUNG

Nach einem akuten Koronarsyndrom (ACS) ist die Gefahr des Auftretens erneuter ischämischer Ereignisse im Sinne von rekurrierenden Myokardinfarkten und Stentthrombosen erhöht. Gleichzeitig steigt mit der antiaggregatorischen und ggf. antikoagulatorischen Therapie vor allem bei gleichzeitiger Indikation zur oralen Antikoagulation das Risiko für Blutungsereignisse deutlich an. Der folgende Artikel soll auf Grundlage der aktualisierten ESC-Leitlinien zur myokardialen Revaskularisation, STEMI und NSTE-ACS sowie des im Jahre 2017 erschienenen fokussierten Updates der dualen Plättchenhemmung eine Übersicht über die derzeitigen Empfehlungen zur Plättchenhemmung und Antikoagulation beim ACS geben.

• Literatur

• 1 Patrono C, Andreotti F, Arnesen H. et al. Anti- platelet agents for the treatment and prevention of atherothrombosis. Eur Heart J 2011; 32: 2922-2932
• 2 Antithrombotic Trialists Collaboration Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86
• 3 Baigent C, Blackwell L, Collins R. et al. Aspirin in the primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-1860
• 4 Roffi M, Patrono C, Collet JP. et al. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST- segment elevation. (The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)). Eur Heart J 2016; 37: 267-315
• 5 Ibánez B, James S, Agewall S. et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation (The Task Force for the management of acute myocardial infarction in patients presenting with ST- segment elevation of the European Society of Cardiology (ESC)). Eur Heart J 2018; 39: 119-177
• 6 Mehta SR, Yusuf S, Peters RJ. et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet 2001; 358: 527-533
• 7 Wiviott SD, Braunwald E, McCabe CH. et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015
• 8 Montalescot G, Bolognese L, Dudek D. et al. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med 2013; 369: 999-1010
• 9 Wallentin L, Becker RC, Budaj A. et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-1057
• 10 Steg PG, Bhatt DL, Hamm CW. et al CHAMPION Investigators. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: A pooled analysis of patient-level data. Lancet 2013; 382: 1981-1992
• 11 Neumann FJ, Sousa-Uva M, Ahlsson A. et al. ESC/EACT Guidelines on myocardial revascularization. Eur Heart J 2018; 00: 1-96
• 12 Bhatt DL, Fox KA, Hacke W. et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354: 1706-1717
• 13 Valgimigli M, Bueno H, Byrne RA. et al. ESC Scientific Document Group; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2018; 39: 213-260
• 14 Bonaca MP, Bhatt DL, Cohen M. et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015; 372: 1791-1800
• 15 Mega JL, Braunwald E, Wiviott SD. et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366: 9-19
• 16 Eikelboom JW, Connolly SJ, Bosch J. et al. COMPASS Investigators. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med 2017; 377: 1319-1330
• 17 Sibbing D, Aradi D, Jacobshagen C. et al. TROPICAL-ACS Investigators. A randomised, open-label, multicentre trial. Lancet 2017; 390: 1747-1757
• 18 Lamberts M, Gislason GH, Olesen JB. et al. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention. J Am Coll Cardiol 2013; 62: 981-989
• 19 Gibson CM, Mehran R, Bode C. et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med 2016; 375: 2423-2434
• 20 Cannon CP, Bhatt DL, Oldgren J. et al. DUAL RE-Steering Committee PCI and Investigators. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 2017; 377: 1513-1524